4DMT Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants

Core Viewpoint - 4D Molecular Therapeutics has announced an underwritten offering of 8,385,809 shares of common stock and pre-funded warrants, aiming to raise approximately $100 million before expenses [1] Group 1: Offering Details - The common stock is priced at $10.51 per share, while pre-funded warrants are priced at $10.5099 each, reflecting a slight discount due to the exercise price [1] - The offering is expected to close on November 7, 2025, pending customary closing conditions [1] - Leerink Partners, Evercore ISI, and Cantor are acting as joint book-running managers, with RBC Capital Markets as a co-manager for the offering [2] Group 2: Company Overview - 4D Molecular Therapeutics is a late-stage biotechnology company focused on disease-targeted therapeutics that aim to transform treatment paradigms [5] - The lead product candidate, 4D-150, targets blinding retinal vascular diseases and is currently in Phase 3 development for wet age-related macular degeneration and diabetic macular edema [5] - The second product candidate, 4D-710, is a genetic medicine for cystic fibrosis, demonstrating successful delivery of the CFTR transgene [5] Group 3: Regulatory Information - A registration statement for the securities has been filed with the U.S. Securities and Exchange Commission and became effective on August 15, 2023 [3] - The offering is being conducted only through a written prospectus, which can be accessed through the SEC's website [3]